Treatment of BRAF-Mutated Metastatic Melanoma: Immunotherapy or Target Therapy?
Metastatic melanoma has been associated with a poor prognosis, with overall survival rates at 5 years of 10%. Until 2011, the only treatments available for metastatic melanoma were chemotherapy and immunotherapy with interleukin-2. The more in-depth knowledge about the molecular biology of melanoma...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Sociedade Portuguesa de Dermatologia e Venereologia,
2021-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|